Biren Amin
Stock Analyst at Piper Sandler
(3.67)
# 904
Out of 5,182 analysts
73
Total ratings
43.08%
Success rate
10.84%
Average return
Main Sectors:
Stocks Rated by Biren Amin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| REGN Regeneron Pharmaceuticals | Assumes: Overweight | $875 | $766.02 | +14.23% | 3 | Mar 31, 2026 | |
| CNTX Context Therapeutics | Maintains: Overweight | $4 → $7 | $2.32 | +201.72% | 2 | Mar 24, 2026 | |
| IMTX Immatics | Assumes: Buy | $18 | $11.15 | +61.43% | 2 | Mar 16, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Overweight | $7 → $8 | $2.35 | +240.43% | 4 | Mar 13, 2026 | |
| KYMR Kymera Therapeutics | Maintains: Overweight | $125 → $140 | $87.17 | +60.61% | 1 | Feb 26, 2026 | |
| OKYO OKYO Pharma | Initiates: Overweight | $7 | $1.59 | +340.25% | 1 | Feb 20, 2026 | |
| CATX Perspective Therapeutics | Initiates: Overweight | $16 | $4.51 | +254.77% | 1 | Feb 19, 2026 | |
| IRD Opus Genetics | Initiates: Overweight | $7 | $5.21 | +34.36% | 1 | Nov 25, 2025 | |
| AAPG Ascentage Pharma Group International | Initiates: Overweight | $48 | $22.34 | +114.86% | 1 | Nov 5, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Neutral | $15 → $16 | $20.42 | -21.65% | 12 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $93 → $98 | $71.67 | +36.74% | 4 | Oct 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $51 → $67 | $9.15 | +632.24% | 2 | Oct 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $21 → $31 | $9.59 | +223.25% | 2 | Oct 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $76 → $95 | $53.24 | +78.44% | 2 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Overweight | $6 | $4.55 | +31.87% | 1 | Jul 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $17 | $8.22 | +106.81% | 2 | May 16, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $38 | $39.44 | -3.65% | 1 | Mar 31, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $12 | $5.21 | +130.33% | 1 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $74 → $71 | $32.80 | +116.46% | 2 | Feb 6, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $35 | $10.22 | +242.47% | 1 | Dec 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $21 | $22.99 | -8.66% | 3 | Nov 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $91 → $115 | $115.05 | -0.04% | 2 | Nov 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $40 → $32 | $40.94 | -21.84% | 2 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $7 → $3 | $3.76 | -20.21% | 1 | Jul 19, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $120 → $70 | $3.89 | +1,699.49% | 2 | May 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $2,550 | $5.16 | +49,318.60% | 1 | Jan 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $24 | $1.60 | +1,400.00% | 1 | Oct 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $34 | $6.40 | +431.25% | 1 | Oct 19, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $1,050 → $500 | $0.15 | +324,575.32% | 2 | Sep 14, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $16 → $10 | $4.45 | +124.72% | 1 | Jun 1, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $101 | $51.27 | +97.00% | 1 | Nov 9, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $66 → $69 | $130.19 | -47.00% | 1 | Oct 3, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $155 | $435.10 | -64.38% | 5 | Jul 11, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $136 | $6.84 | +1,888.30% | 4 | Mar 6, 2017 |
Regeneron Pharmaceuticals
Mar 31, 2026
Assumes: Overweight
Price Target: $875
Current: $766.02
Upside: +14.23%
Context Therapeutics
Mar 24, 2026
Maintains: Overweight
Price Target: $4 → $7
Current: $2.32
Upside: +201.72%
Immatics
Mar 16, 2026
Assumes: Buy
Price Target: $18
Current: $11.15
Upside: +61.43%
Allogene Therapeutics
Mar 13, 2026
Maintains: Overweight
Price Target: $7 → $8
Current: $2.35
Upside: +240.43%
Kymera Therapeutics
Feb 26, 2026
Maintains: Overweight
Price Target: $125 → $140
Current: $87.17
Upside: +60.61%
OKYO Pharma
Feb 20, 2026
Initiates: Overweight
Price Target: $7
Current: $1.59
Upside: +340.25%
Perspective Therapeutics
Feb 19, 2026
Initiates: Overweight
Price Target: $16
Current: $4.51
Upside: +254.77%
Opus Genetics
Nov 25, 2025
Initiates: Overweight
Price Target: $7
Current: $5.21
Upside: +34.36%
Ascentage Pharma Group International
Nov 5, 2025
Initiates: Overweight
Price Target: $48
Current: $22.34
Upside: +114.86%
Sarepta Therapeutics
Oct 30, 2025
Maintains: Neutral
Price Target: $15 → $16
Current: $20.42
Upside: -21.65%
Oct 30, 2025
Maintains: Overweight
Price Target: $93 → $98
Current: $71.67
Upside: +36.74%
Oct 10, 2025
Maintains: Overweight
Price Target: $51 → $67
Current: $9.15
Upside: +632.24%
Oct 3, 2025
Maintains: Overweight
Price Target: $21 → $31
Current: $9.59
Upside: +223.25%
Sep 25, 2025
Maintains: Overweight
Price Target: $76 → $95
Current: $53.24
Upside: +78.44%
Jul 10, 2025
Assumes: Overweight
Price Target: $6
Current: $4.55
Upside: +31.87%
May 16, 2025
Maintains: Overweight
Price Target: $20 → $17
Current: $8.22
Upside: +106.81%
Mar 31, 2025
Initiates: Overweight
Price Target: $38
Current: $39.44
Upside: -3.65%
Feb 19, 2025
Initiates: Overweight
Price Target: $12
Current: $5.21
Upside: +130.33%
Feb 6, 2025
Maintains: Overweight
Price Target: $74 → $71
Current: $32.80
Upside: +116.46%
Dec 2, 2024
Initiates: Overweight
Price Target: $35
Current: $10.22
Upside: +242.47%
Nov 14, 2024
Maintains: Overweight
Price Target: $23 → $21
Current: $22.99
Upside: -8.66%
Nov 8, 2024
Maintains: Overweight
Price Target: $91 → $115
Current: $115.05
Upside: -0.04%
Nov 6, 2024
Maintains: Neutral
Price Target: $40 → $32
Current: $40.94
Upside: -21.84%
Jul 19, 2024
Downgrades: Hold
Price Target: $7 → $3
Current: $3.76
Upside: -20.21%
May 19, 2023
Maintains: Buy
Price Target: $120 → $70
Current: $3.89
Upside: +1,699.49%
Jan 11, 2021
Initiates: Buy
Price Target: $2,550
Current: $5.16
Upside: +49,318.60%
Oct 30, 2020
Initiates: Buy
Price Target: $24
Current: $1.60
Upside: +1,400.00%
Oct 19, 2020
Initiates: Buy
Price Target: $34
Current: $6.40
Upside: +431.25%
Sep 14, 2020
Downgrades: Hold
Price Target: $1,050 → $500
Current: $0.15
Upside: +324,575.32%
Jun 1, 2020
Downgrades: Hold
Price Target: $16 → $10
Current: $4.45
Upside: +124.72%
Nov 9, 2017
Initiates: Buy
Price Target: $101
Current: $51.27
Upside: +97.00%
Oct 3, 2017
Maintains: Buy
Price Target: $66 → $69
Current: $130.19
Upside: -47.00%
Jul 11, 2017
Initiates: Buy
Price Target: $155
Current: $435.10
Upside: -64.38%
Mar 6, 2017
Initiates: Buy
Price Target: $136
Current: $6.84
Upside: +1,888.30%